vs
Side-by-side financial comparison of OLIN Corp (OLN) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.7B, roughly 1.4× OLIN Corp). Zoetis runs the higher net margin — 25.3% vs -8.6%, a 33.9% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -0.4%). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 0.9%).
Olin Corporation is an American manufacturer of ammunition, chlorine, and sodium hydroxide. The company traces its roots to two companies, both founded in 1892: Franklin W. Olin's Equitable Powder Company and the Mathieson Alkali Works. Accidents at Olin chemical plants have exposed employees and nearby residents to health hazards.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
OLN vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.4B |
| Net Profit | $-143.2M | $603.0M |
| Gross Margin | 1.9% | 70.2% |
| Operating Margin | -9.4% | 31.9% |
| Net Margin | -8.6% | 25.3% |
| Revenue YoY | -0.4% | 3.0% |
| Net Profit YoY | -1517.8% | 3.8% |
| EPS (diluted) | $-1.25 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | $2.4B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.6B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.6B | $2.2B |
| Q4 25 | $-143.2M | $603.0M | ||
| Q3 25 | $43.7M | $721.0M | ||
| Q2 25 | $-2.8M | $718.0M | ||
| Q1 25 | $1.2M | $631.0M | ||
| Q4 24 | $10.1M | $581.0M | ||
| Q3 24 | $-25.2M | $682.0M | ||
| Q2 24 | $72.3M | $624.0M | ||
| Q1 24 | $47.8M | $599.0M |
| Q4 25 | 1.9% | 70.2% | ||
| Q3 25 | 10.7% | 71.5% | ||
| Q2 25 | 7.9% | 73.6% | ||
| Q1 25 | 9.0% | 72.0% | ||
| Q4 24 | 9.4% | 69.5% | ||
| Q3 24 | 8.5% | 70.6% | ||
| Q2 24 | 14.5% | 71.7% | ||
| Q1 24 | 12.7% | 70.6% |
| Q4 25 | -9.4% | 31.9% | ||
| Q3 25 | 4.8% | 37.0% | ||
| Q2 25 | 2.0% | 36.7% | ||
| Q1 25 | 2.7% | 36.5% | ||
| Q4 24 | 2.8% | 31.6% | ||
| Q3 24 | 1.0% | 36.6% | ||
| Q2 24 | 8.3% | 33.0% | ||
| Q1 24 | 5.9% | 34.1% |
| Q4 25 | -8.6% | 25.3% | ||
| Q3 25 | 2.6% | 30.0% | ||
| Q2 25 | -0.2% | 29.2% | ||
| Q1 25 | 0.1% | 28.4% | ||
| Q4 24 | 0.6% | 25.1% | ||
| Q3 24 | -1.6% | 28.6% | ||
| Q2 24 | 4.4% | 26.4% | ||
| Q1 24 | 2.9% | 27.4% |
| Q4 25 | $-1.25 | $1.37 | ||
| Q3 25 | $0.37 | $1.63 | ||
| Q2 25 | $-0.01 | $1.61 | ||
| Q1 25 | $0.01 | $1.41 | ||
| Q4 24 | $0.10 | $1.29 | ||
| Q3 24 | $-0.21 | $1.50 | ||
| Q2 24 | $0.62 | $1.37 | ||
| Q1 24 | $0.40 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | — |
| Total DebtLower is stronger | $2.8B | — |
| Stockholders' EquityBook value | $1.8B | $3.3B |
| Total Assets | $7.3B | $15.5B |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $175.6M | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $1.8B | $3.3B | ||
| Q3 25 | $2.0B | $5.4B | ||
| Q2 25 | $2.0B | $5.0B | ||
| Q1 25 | $2.0B | $4.7B | ||
| Q4 24 | $2.0B | $4.8B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $2.1B | $5.0B | ||
| Q1 24 | $2.2B | $5.1B |
| Q4 25 | $7.3B | $15.5B | ||
| Q3 25 | $7.6B | $15.2B | ||
| Q2 25 | $7.7B | $14.5B | ||
| Q1 25 | $7.7B | $14.1B | ||
| Q4 24 | $7.6B | $14.2B | ||
| Q3 24 | $7.5B | $14.4B | ||
| Q2 24 | $7.7B | $14.2B | ||
| Q1 24 | $7.6B | $14.3B |
| Q4 25 | 1.55× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.34× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.24× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $321.2M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $321.2M | $893.0M | ||
| Q3 25 | $26.7M | $938.0M | ||
| Q2 25 | $212.3M | $486.0M | ||
| Q1 25 | $-86.0M | $587.0M | ||
| Q4 24 | $141.7M | $905.0M | ||
| Q3 24 | $189.9M | $951.0M | ||
| Q2 24 | $90.6M | $502.0M | ||
| Q1 24 | $81.0M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | $-44.4M | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | $-147.4M | $438.0M | ||
| Q4 24 | $90.7M | $689.0M | ||
| Q3 24 | $146.6M | $784.0M | ||
| Q2 24 | $34.1M | $370.0M | ||
| Q1 24 | $36.7M | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | -2.6% | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | -9.0% | 19.7% | ||
| Q4 24 | 5.4% | 29.7% | ||
| Q3 24 | 9.2% | 32.8% | ||
| Q2 24 | 2.1% | 15.7% | ||
| Q1 24 | 2.2% | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | 4.2% | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | 3.7% | 6.7% | ||
| Q4 24 | 3.1% | 9.3% | ||
| Q3 24 | 2.7% | 7.0% | ||
| Q2 24 | 3.4% | 5.6% | ||
| Q1 24 | 2.7% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 0.61× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | -71.67× | 0.93× | ||
| Q4 24 | 14.03× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | 1.25× | 0.80× | ||
| Q1 24 | 1.69× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLN
| Chlorinechlorinederivativesandothercoproducts | $456.2M | 27% |
| Causticsoda | $400.2M | 24% |
| Militaryandlawenforcement | $304.6M | 18% |
| Epoxyresins | $194.9M | 12% |
| Aromaticsandallylics | $164.4M | 10% |
| Commercial | $144.8M | 9% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
